Mcgill University

Nitto-denko Corporation

Biota Scientific Management Pty Ltd

Migenix, Inc.

Janssen Pharmaceutica Nv

Isis Pharmaceuticals, Inc.

Janssen Biopharma, Inc.

Micrologix Biotech Inc.

Biota, Inc.

Yi Jin

Zhili Xin

Eric Marsault

George Just

Phillip Dan Cook

Lei Yu

Marija Prhavc

Vivek K Rajwanshi

Radhakrishnan P Iyer

Kwok Yin Tsang

Arlene Roland

Wenqiang Zhou

Guangyi Wang

Thomas W Bruice

Hao Bai

Janet M Leeds

Jennifer L Brooks

Jianchao Wang

Nicholas A Boyle

Maria Eugenia Ariza

Patrick C Fagan

Kathleen D Tucker

Leonid Beigelman

Sergei M Gryaznov

Antitsa Dimitrova Stoycheva

Vivek Kumar Rajwanshi

Rajendra K Pandey

John Nicholas Lambert

Lakshmipathi Pandarinathan

Bharat Baral

Deborah K Ewing, Legal Representative

Vasanthankumar Rajappan

Kandasamy Sakthivel

Muthiah Manoharan

Seiji Nukui

Sang Van

Gang Zhao

Hai Wang

Chunfeng Yin

Jin Hong

Xiaoli Fu

Xinghe Wang

Zhongling Feng

Gregory J Ewing

Saul Martinez Montero

Vasanthakumar Rajappan

Sanjib Kumar Das

Fu Chen

Gregory Ewing

Modified oligonucleotides comprising modifications at the 2' and/or 3′ position(s) along with methods of making and use, e.g., against HBV are disclosed.

Modified oligonucleotides and methods of use

Modified oligonucleotides comprising modifications at the 2' and/or 3&#x2032; positions(s) along with methods of making and use, e.g., against HBV are disclosed.

Various biodegradable polyglutamate-amino acids comprising recurring units of the general formulae (I) and (II) are prepared. Such polymers are useful for variety of drug, biomolecule and imaging agent delivery applications.

Polyglutamate-amino acid conjugates and methods

Described herein are methods of lowering the endotoxin content from a polyanionic polymer conjugate. In particular, methods of reducing the endotoxin content from a polyanionic polymer conjugate that can be useful for a variety of drug delivery applications are described herein.

Reduction of endotoxins from polyanionic polymer conjugates

Described herein are processes of making biocompatible water-soluble polymers conjugates. In particular, large scale processes of making poly(L-&#x3b3;-glutamyl-glutamate) conjugates that can be useful for a variety of drug delivery applications are described herein.

Large scale process for preparing poly (glutamyl-glutamate) conjugates

This application relates generally to biocompatible water-soluble polymers with pendant functional groups and methods for making them, and particularly to co-polymer polyglutamate amino acid conjugates useful for a variety of anti-cancer drug delivery applications.

Co-polymer conjugates

This application relates generally to biocompatible water-soluble polymers with pendant functional groups and methods for making them, and particularly to polyglutamate amino acid conjugates that can include a linker to a compound that can include a drug, and their use for a variety of drug delivery applications, e.g., anticancer.

Polymer conjugates with a linker

The present invention relates to nucleoside diphosphate mimics and nucleoside triphosphate mimics, which contain diphosphate or triphosphate moiety mimics and optionally sugar-modifications and/or base-modifications. The nucleotide mimics of the present invention, in a form of a pharmaceutically acceptable salt, a pharmaceutically acceptable prodrug, or a pharmaceutical formulation, are useful as antiviral, antimicrobial, and anticancer agents. The present invention provides a method for the treatment of viral infections, microbial infections, and proliferative disorders. The present invention also relates to pharmaceutical compositions comprising the compounds of the present invention optionally in combination with other pharmaceutically active agents.

Nucleotide mimics and their prodrugs

Nucelosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.

Tricyclic nucleosides or nucleotides as therapeutic agents

The invention provides compounds capable of treating against hepatitis infections, particularly hepatitis B viral infections. Compounds of the invention are nucleic acid-based and preferably comprise 2, 3, 4, 5 or 6 nucleoside units.

Nucleic acid-based compounds and methods of use thereof

Nucleosides and nucleotides containing a tricyclic base portion thereof are useful for treating infectious diseases and proliferative disorders, such as viral infections or cancer respectively.

Growing community of inventors

Carlsbad, CA, United States of America

Yi Jin